OBJECTIVES: To analyse the improvement in both symptoms (IPSS questionnaire) and uroflowmetry parameters (Qmax) after treatment with different alpha-blockers in patients with LUTS and BPH.
The efficacy of alpha-blocker treatment on urodynamic parameters was also analysed in some patients.
METHODS: An epidemiological, retrospective, multi-centre, and observational study. Twenty-five (24) Spanish healthcare centres recruited 443 patients with LUTS and BPH, and no other concurrent urological disease, they were on treatment with alpha-blockers. The study variables (demographic, physical examination, IPSS, and urodynamic) were collected retrospectively at start of the study (at least 12 weeks after the start of treatment). Two-tailed statistical tests were performed with a 5% significance level using a SAS statistical software package version 9.0.
RESULTS: The IPSS score improved after 12 weeks of treatment (p< 0.0001). The quality of life perception significantly improved (p< 0.0001). The voiding volume and Qmax increased (p< 0.0001) and the post-void residual urine decreased (p< 0.0001) after treatment both in patients with moderate and severe symptoms. Other than filling pressure and involuntary contraction amplitude (p>0.05), all cystomanometry parameters improved (p<0.05). There were statistically significant differences (p< 0.05) in the pressure flow study values, except for the detrusor contractility rate.
CONCLUSION: Alpha-blocker drug treatment of LUTS in patients with BPH leads to a significant improvement in symptoms and bladder voiding urodynamic parameters.
Written by:
Salinas J, Ural G. Are you the author?
Servicio de Urología, Hospital Clínico, Madrid, España.
Reference: Arch Esp Urol. 2015 Mar;68(2):161-171.
PubMed Abstract
PMID: 25774823